A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This trial is aim to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy people 1 to 12 years of age.1200 healthy subjects aged 1-12 years were enrolled after their guardians passed the informed consent, inclusion and exclusion criteria screening in turn. Three batches were randomized in a 1:1: 1 ratio, with 400 subjects in each batch.All subjects received 1 dose of trial vaccine (Batch 1 or Batch 2 or Batch 3) and all were collected Blood samples were collected from subjects before vaccination, on Day 30 after vaccination for serum neutralizing antibody testing to evaluate immunogenicity, and Safety observations were performed until 6 months post-vaccination in all subjects.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental Group1 Single subcutaneous injection of the investigational vaccine (0.5ml) |
Biological: Investigational live attenuated varicella vaccine (lot 1)
0.5ml/vial
|
| Experimental: Experimental Group2 Single subcutaneous injection of the investigational vaccine (0.5ml) |
Biological: Investigational live attenuated varicella vaccine (lot 2)
0.5ml/vial
|
| Experimental: Experimental Group3 Single subcutaneous injection of the investigational vaccine (0.5ml) |
Biological: Investigational live attenuated varicella vaccine (lot 3)
0.5ml/vial
|
Outcome Measures
Primary Outcome Measures
- Geometric mean titers (GMT) of anti-VZV neutralizing antibodies [30 days after vaccination]
Geometric mean titers (GMT) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization
Secondary Outcome Measures
- Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies [30 days after vaccination]
Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization
- Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies [30 days after vaccination]
Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies 30 days after vaccination in the whole population
- The incidences of adverse events (AEs) [30 days after vaccination]
AEs occurred witnin 30 days after vaccination will be collected
- The incidences of serious adverse events (SAEs) and Adverse Event of Special Interest(AESI) [6 months after vaccination]
SAEs and AESI occurred witnin 6 months after vaccination will be collected
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 1 to 12 years on the day of enrollment ,male or female, and able to provide legal identity certificate.
-
Subjects and/or guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent form.
-
Axillary temperature ≤ 37.0 ° C on the day of enrollment.
Exclusion Criteria:
-
Previous vaccination against varicella (eg, varicella vaccine, measles + varicella vaccine).
-
History of varicella or herpes zoster infection, or exposure to varicella/herpes zoster within 30 days of enrollment or suspected varicella/herpes zoster;
-
Current use of salicylates (including salicylic acid, aspirin, diflunisal, p-aminosalicylic acid (sodium), salsalsalate, benorilate, etc.), or planned long-term use during the study.
-
Febrile illness (axillary temperature ≥ 38.5 ° C) or use of antipyretic, analgesic, and anti-allergic drugs (eg, acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination.
-
History of allergy to vaccine ingredients and excipients or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria.
-
History of epilepsy, convulsions, or convulsions, or a family history of psychosis.
-
Impaired immune function or has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases.
-
Patients suffering from serious congenital malformations, genetic diseases, serious cardiovascular diseases, serious liver/kidney diseases, diabetes with complications, malignant tumors, severe malnutrition.
-
Immunosuppressant therapy such as chronic oral or injectable glucocorticoid therapy (≥ 14 days at doses ≥ 2 mg/kg/day or ≥ 20 mg/day prednisone or equivalent prednisone dose) within 3 months prior to administration of trial vaccine or planned 30 days following administration, but not limited by topical use (eg, ointment, eye drops, inhalers, or nasal sprays).
-
Receiving blood/blood-related products or immunoglobulins 3 months before vaccination or planning to use such products 30 days after vaccination.
-
Vaccination with a live attenuated vaccine within 30 days or any vaccine within 14 days prior to vaccination.
-
Absence of spleen or splenectomy due to any condition such as splenectomy.
-
Patients with a history of thrombocytopenia or other coagulation disorders, which may cause contraindications to subcutaneous injection.
-
Infectious, suppurative and allergic skin diseases.
-
Participating in other investigational or non-registered product (drug, vaccine or device, etc.) clinical trials, or planning to participate in other clinical trials before the end of this clinical trial.
-
Subject has any other factor that, in the judgment of the investigator, would make the subject unsuitable for participation in the clinical trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Xinyi Center for Disease Control and Prevention | Xuzhou | Jiangsu | China | 221600 |
Sponsors and Collaborators
- China National Biotec Group Company Limited
- Beijing Institute of Biological Products Co Ltd.
- Jiangsu Province Center for Disease Control and Prevention
Investigators
- Principal Investigator: Hongxing Pan, Jiangsu Province Centers for Disease Control and Prevention
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CNBG-BIBP-VZV-08